UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer

Advances in Experimental Medicine and Biology

Volumn 624, Issue , 2008, Pages 162-178

  Rass, Knuth ^a   Reichrath, Jörg ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MSH2;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CAUCASIAN; CELL DAMAGE; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENE MUTATION; HUMAN; MELANOGENESIS; MELANOMA; MISMATCH REPAIR; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN PROTECTION; SOLAR RADIATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION; XERODERMA PIGMENTOSUM; ANIMAL; GENETICS; SKIN TUMOR;

ANIMALIA; ERINACEIDAE; MAMMALIA; MUS; XIPHOPHORUS;

ANIMALS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DNA DAMAGE; DNA REPAIR; HUMANS; MELANOMA; SKIN NEOPLASMS; ULTRAVIOLET RAYS; XERODERMA PIGMENTOSUM;

EID: 42949122558     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77574-6_13     Document Type: Review

References (113)

1. Gates FL. On nuclear derivatives and lethal action of ultraviolet light. Science 1928; 68:479-480.
2. Hollaender A, Emmons CW. Wavelength dependence of mutation production in the ultraviolet with special emphasis on fimgi. Cold Spring Harbor Symp Quand Biol 1941; 9:179-186.
3. Setlow RB. DNA damage and repair: a photobiological odyssey. Photochem Photobiol 1997; 65S:119S-122S.
4. Coohill TP. Historical aspects of ultraviolet action spectroscopy. Photochem Photobiol 1997; 65S:123S-128S.
5. De Grujil FR. Skin cancer and solar uv radiation. Eur J Cancer 1999; 35:2003-2009.
6. Beukers R, Berends W. Isolation and identification of the irradiation product of thymine. Biochim Biophys Acta 1960; 41:550-551.
7. Setlow RB, Carrier WL. Pyrimidine dimers in ultraviolet-irradiated DNA's. J Mol Biol 1966; 17:237-254.
8. Varghese AJ, Patrick MH. Cytosine derived hetcroadduct formation in ultraviolet-irradiated DNA. Nature 1969; 223:299-300.
9. Lill PH. Latent period and antigenicity of murine tumors induced in C3H mice by short-wavelength ultraviolet radiation. J Invest Dermatol 1983; 81:342-6.
10. Peak JG, Peak MJ. Comparison of initial yields of DNA-to-protein crosslinks and single-strand breaks induced in cultured human cells by far- and near-ultraviolet light, blue Ught and X-rays. Mutation Res 1991; 246:187-191.
11. Van Weelden H, Van der Putte SCJ, Toonstra J et al. UVA-induced tumours in pigmented hairless mice and the carcinogenic risks of tanning with UVA. Arch Dermatol 1990; 282:289-294.
12. Staberg B, Wiilf HC, Klemp P et al. The carcinogenic effect of UV-A irradiation. J Invest Dermatol 1983; 81:517-519.
13. Talve L, Stenbaeck TL, Jansen CT. UVA irradiation increases the incidence of epithelial tumors in UVB-irradiated hairless mice. Photodermatol Photoimmunol Photomed 1990; 7:109-115.
14. Peak MJ, Peak JG. Molecular photobiology of UVA. In: Urbach F, Gange RW, eds. The biological effects of UVA irradiation. New York: Praeger, 1986; 42-52.
15. Setlow RB, Carrier WL. The disappearance of thymine dimers from DNA: an error-correcting mechanism. Proc Natl Acad Sci USA 1964; 51:226-231.
16. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular and neurologic abnormalities in 830 published cases (review article). Arch Dermatol 1987; 123:241-250.
17. Brash ED, Rudolph JA, Simon JA et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88:10124-10128.
18. Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968; 218:652-656.
19. Moriwaki SI, Kraemer KH. Xeroderma pigmentosum-bridging a gap between clinic and laboratory. Photodermatol Photoimmunol Photomed 2001; 17:47-54.
20. Sarasin A. The molecular pathways of ultraviolet-induced carcinogenesis. Mutat Res 1999; 428:5-10.
21. Strauss B, Rabkin S, Sagher D et al. The role of DNA polymerase in base substitution mutagenesis on non-instructional templates. Biochimie 1982; 64:829-838.
22. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol 2002; 146(Suppl. 61):20-23.
23. Ziegler AD, Leffel DJ, Kunala S et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90:4216-4220.
24. Quinn AG, Healy E, Rehman I et al. Microsatellite instabiUty in human nonmelanoma and melanoma skin cancer. J Invest Dermatol 1995; 104:309-312.
25. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027-1038.
26. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994; 54:5059-5063.
27. Peltomaki P, Aaltonen LA, Sistonen P et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993; 260:810-812.
28. Palombo F, Hughes M, Jiricny J et al. Mismatch repair and cancer. Nature 1994; 367:417.
29. Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Himi Mol Genet 2001; 10:735-740.
30. Kruse R, Rutten A, Lamberti C et al. Muir-Torre phenotype has a frequency of DNA mismatchrepair- gene mutations similar to that in hereditary nonpolyposis colorectal cancer famihes defined by the Amsterdam criteria. Am J Hum Genet 1998; 63:63-70.
31. Suspiro A, Fidalgo P, Cravo M et al. The Muir-Torre syndrome: a rare variant of hereditary nonpolyposis colorectal cancer associated with hMSH2 mutation. Am J Gastroenterol 1998; 93:1572-4.
32. Mathiak M, Ruttcn A, Mangold E ct al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLHl germlinc mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 2002; 26:338-43.
33. Mellon I, Champe GN. Products of DNA mismatch repair genes mutS and mutL are required for transcription-coupled nucleotide-cxcision repair of the lactose operon in Escherichia coli. Proc Natl Acad Sci USA 1996; 93:1292-1297.
34. Mellon I, Rajpal DK, Koi M et al. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 1996; 272:557-560.
35. Wang H, Lawrence CW, Li GM et aL Specific binding of human MSH2/MSH6 mismatch-repair protein heterodimers to DNA incorporating thymine- or uracil-containing UV light photoproducts opposite mismatched bases. J Biol Chem 1999; 274:16894-16900.
36. Scherer SJ, Maier SM, Seifert M et al. P53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J Biol Chem 2000; 275:37469-73.
37. Rochette PJ, Bastien N, McKay BC et al. Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLHl or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair. Oncogene 2002; 21:5743-52.
38. Vitasa BC, Taylor HR, Strickland PJ et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland Watermen. Cancer 1990; 65:2811-2817.
39. Unna PG. Histopathologic der Hautkrankheiten. Berlin, August Hirschwald, 1894.
40. Dubreuilh W. Des hyperkeratoses circonscriptes. Ann Derm et Syph 1896; 7:1158-1204.
41. Findlay GM. Ultraviolet light and skin cancer. Lancet 1928; 2:1070-1073.
42. De Grujil FR, Sterenborg HJCM, Forbes PD et al. Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res 1993; 53:53-60.
43. De Grujil FR, Van der Leun JC. Estimate of the wavelength dependency of ultraviolet carcinogenesis in humans and its relevance to risk assessments of a stratopheric ozone depletion. Health Phys 1994; 67:319-325.
44. Freeman SE, Hacham H, Gauge RW et al. Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolight Ught. Proc Natl Acad Sci USA 1989; 86:5605-5609.
45. Van Kranen HJ, De Laat A, Van de Ven J et al. Low incidence of p53 mutations in UVA (365-nm)-induced skin tumours in hairless mice. Cancer Res 1997; 57:1238-1240.
46. Riinger TM. Role of UVA in the pathogenesis of melanoma and nonmelanoma skin cancer. A short review. Photodermatol Photoimmunol Photomed 1999; 15:212-6.
47. Hurwitz RM, Monger LE. Solar keratosis: an evolving squamous cell carcinoma. Benign or malignant? Dermatol Surg 1995; 21:184.
48. Babilas P, Landthaler M, Szeimies RM. Actinic keratoses. Hautarzt 2003; 54:551-562.
49. Vogclstein B, Kinzler KW. P53 frmction and dysfrmction. Cell 1992; 70:523-526.
50. Kuerbitz SJ, Plunkett BS, Walsh WV et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Nad Acad Sci USA 1992; 89:7491-7495.
51. Donehower LA, Bradley A. The timior suppressor p53. Biochim Biophys Acta 1993; 1155:181-205.
52. Shieh SY, Ikeda M, Taya Y et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-334.
53. Freedman DA, Wu L, Levine AJ. Fimctions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55:96-107.
54. Grecnblatt MS, Bennett WP, HoUstein M et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878.
55. Brash DE, Ziegler A, Jonason AS et al. Sunlight and sunburn in human skin cancer: p53, apoptosis and tumor promotion. J Invest Dermatol Symp Proc 1996; 1:136-142.
56. Li G, Tron VA, Ho V. Induction of squamous cell carcinoma in p53-deficient mice after ultraviolet irradiation. J Invest Dermatol 1998; 110:72-75.
57. Nigro JM, Baker SJ, Prcisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-708.
58. Rehman I, Quinn AG, Healy E et al. High frequncy of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 1994; 344:788-789.
59. Scherer SJ, Welter C, Zang KD et al. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem Biophys Res Commun 1996; 221:722-8.
60. Scherer SJ, Scib T, Seitz G et al. Isolation and characterization of the himian mismatch repair gene hMSH2 promoter region. Hum Genet 1996; 97:114-116.
61. Rass K, Gutwein P, Miiller SM et al. Immunohistochemical analysis of DNA mismatch repair enzyme hMSH2 in normal human skin and basal cell carcinomas. Histochem J 2000; 32:93-97.
62. Liang SB, Furihata M, Takcuchi T ct al. Reduced human mismatch repair protein expression in the development of precancerous skin lesions to squamous cell carcinoma. Virchows Arch 2001; 439:622-627.
63. Lage H, Christmann M, Kern MA et al. Expression of DNA repair proteins hMSH2, hMSH6, hMLHl, 06-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 1999; 80:744-750.
64. Rass K, Gutwein P, Welter C et al. Expression of DNA mismatch repair enzyme hMSH2 in epithelial skin tumours and its induction by ultraviolet B radiation in vitro. Submitted for publication.
65. Zanetti R, Rosso S, Martinez C et al. The multicentre south European study "hclios" I: skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1440-1446.
66. Rosso S, Zanetti T, Martinez C et al. The multicentre south European study "helios" II: diflPerent sun exposure patterns in the etiology of basal and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1447-1454.
67. Corona R, Dogliotti E, D'Ericco M et al. Risk factors for basal cell carcinoma in a Mediterranean population. Arch Dermatol 2002; 137:1162-1168.
68. Gallagher RP, Hill GB, Bajdik CD et al. Sunlight exposure, pigmentary factors and risk of nonmelanocytic skin cancer. Arch Dermatol 1995; 131:157-163.
69. Green A, Wiliams G, Nealc R et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723-729.
70. Marcil I, Stem RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer. Arch Dermatol 2000; 136:1524-1530.
71. Kruger K, Blume-Peytavi U, Orfanos CE. Basal cell carcinoma possibly originate from the outer root sheath and/or the bulge region of the vellus hair follicle. Arch Dermatol Res 1999; 291:253-259.
72. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine 1987; 66:98-113.
73. Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841-851.
74. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668-1671.
75. Bale AE, YU KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001; 10:757-762.
76. Gailani MR, Stahle-Backdahl M, Leffell DJ et al. The role of the human homologue of Drosophila patched in sporadic cell carcinomas. Nat Genet 1996; 14:79-81.
77. Unden AB, Zaphiropoulos PG, Bruce K et al. Human patched (PTCH) mRNA is overcxpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. J Natl Cancer Inst 1996; 88:349-354.
78. Barnes EA, Kong M, Ollendorff V et al. Patched 1 interacts with cyclin Bl to regulate cell cycle progression. EMBO J 2001; 20:2214-2223.
79. Soehnge H, Ouhtit A, Ananthaswamy HN. Mechanisms of induction of skin cancer by UV radiation. Frontiers Bioscicncc 1997; 2:538-551.
80. Lacour JP. Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 2002; 146(S61):17-19.
81. Couv-Privat S, Bouadjar B, Avril MF et al. Significantly high levels of ultraviolet-specific mutations in the Smoothencd gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res 2002; 62:7186-7189.
82. Bodak N, Queille S, Avril MF et al. High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc Natl Acad Sci USA 1999; 96:5117-5222.
83. Eklund LK, Lindstrom E, Unden AB et al. Mutation analysis of the himian homologue of Drosophila patched and the xeroderma pigmentosum complementation group A genes in squamous cell carcinomas of the skin. Mol Carcinog 1998; 21:87-92.
84. Kang SY, Lee KG, Lee W et al. Polymorphisms in the DNA repair gene XRCCl associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population. Cancer Sci 2007; [Epub ahead of print].
85. Leibeling D, Laspc P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol 2006; 37(5-7):225-38.
86. Han J, Kraft P, Colditz GA et al. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006; 119(8):1976-84,
87. Markovic SN, Erickson LA, Rao RD et al. Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention and diagnosis. Mayo Clin Proc 2007; 82(3):364-80.
88. Jhappan C, Noonan FP, Mcrlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003; 22(20):3099-112.
89. Noonan FP, Recio JA, Takayama H et al. Neonatal sunburn and melanoma in mice. Nature 2001; 4l3(6853):271-2.
90. Noonan FP, Otsuka T, Bang S et al. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res 2000; 60(l4):3738-43.
91. Kraemer KH, Lee MM, Andrews AD et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130(8):1018-21.
92. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92:874-897.
93. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003; 3:559-570.
94. Neimiann A, Sturgis E, Wei Q. Nucleotide excision repair as a marker for susceptibiUty to tobaccorelated cancers: A review of molecular epidemiological studies. Mol Carcinog 2005; 42:65-92.
95. Hsu TC, Fuen L, Trizna Z et al. Differential sensitivity among three human subpopulations in response to 4-nitroquinoline-l-oxide and to bleomycin. Int J Oncol 1993; 3:827-830.
96. Roth M, MuUer H, Boyle JM. Immunochemical determination of an initial step in thymine dimer excision repair in xeroderma pigmentosum variant fibroblasts and biopsy material from the normal population and patients with basal cell carcinoma and melanoma. Carcinogenesis 1987; 8:1301-1307.
97. Wei Q, Lee JE, Gershenwald JE et al. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 2003; 95:308-315.
98. Landi MT, Baccarelli A, Tarone RE et al. DNA repair, dysplastic nevi and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 2002; 94:94-101.
99. Hauser JE, Kadekaro AL, Kavanagh RJ et al. Melanin content and MCIR function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Res 2006; 19(4):303-14.
100. Millikan RC, Hummer A, Begg C et al; for the GEM Study Group. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis 2006; 27(3):610-618.
101. Li C, Hu Z, Liu Z et al. Polymorphisms in the DNA Repair Genes XPC, XPD and XPG and Risk of Cutaneous Melanoma: a Case-Control Analysis. Cancer Epidemiol Biomarkers Prev 2006; 15(12):2526-2532.
102. Debniak T, Scott R, Masojc B et al. MCIR common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer 2006; 119(ll):2597-602.
103. Winsey SL, Haldar NA, Marchs HP et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000; 60:5612-5616.
104. Tomescu D, Kavanagh G, Ha T et al. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis 2001; 22:403-408.
105. Baccarelli A, Calista D, Minghetti P et al. XPD gene polymorphism and host characteristics in the assocation with cutaneous maUgnant melanoma risk. Br J Cancer 2004; 90:497-502.
106. Blankenburg S, Konig I, Moessner R et al. No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma. Eur J Hum Genet 2005; 13:253-255.
107. Han J, Colditz GA, Liu JS et al. Genetic variation in XPD, sun exposure and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1539-1544.
108. Blankenburg S, Konig IR, Moessner R et al. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis 2005; 26:1085-1090.
109. Seifert M, Bohm M, Lobrich M et al. The DNA-mismatch repair enzyme hMSH2 modulates UV-Binduced cell cycle arrest and apoptosis in melanoma cells. J Invest Dermatol, in press.
110. Hawn MT, Umar A, Carethcrs JM et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 1995; 55(17):3721-5.
111. Davis TW, Wilson-van Patten C, Meyers M et al. Defective expression of the DNA mismatch repair protein, MLHl, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 1998; 58(4):767-78.
112. Lan Z, Sever-Chroneos Z, Strobeck MW et al. DNA damage invokes mismatch repair-dependent cyclin Dl attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem 2002; 277(10):8372-81.
113. Rass K, Gutwein P, Welter C et al. DNA-mismatch-repair enzyme hMSH-2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. Histochem J 2001; 33:459-467.